SunRegen
Allschwil
About SunRegen
SunRegen is a biopharmaceutical company with a mission to develop drugs to treat neurodegenerative diseases. They focus on innovative treatments for patients suffering from neurological, neuromuscular and ophthalmic diseases. Their first product candidates in development target primary optical atrophy. They are further evaluating them for use in serious neurological / neuromuscular diseases such as ALS, Huntington's, Alzheimer’s and Parkinson’s disease. Their team is composed of passionate and innovative founders and experts who have solid track records in drug development and clinical research in multinational pharmaceutical companies or management experience in international technology enterprises. Their determination in bringing life-changing treatments to patients encompasses everything they do.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $83.3K
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2019)
- Website: sunregen.ch
- Phone: +41 (0)76 480 56 28
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/sunregen-153141 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.